| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Randomized Controlled Trials as Topic | 3 | 2019 | 541 | 0.970 |
Why?
|
| Diet, Reducing | 6 | 2023 | 100 | 0.900 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 151 | 0.770 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 1152 | 0.660 |
Why?
|
| Hypertension | 4 | 2024 | 983 | 0.600 |
Why?
|
| Heart Defects, Congenital | 4 | 2020 | 32 | 0.600 |
Why?
|
| Humans | 55 | 2025 | 32952 | 0.600 |
Why?
|
| Random Allocation | 2 | 2017 | 229 | 0.600 |
Why?
|
| Smoke | 1 | 2019 | 16 | 0.590 |
Why?
|
| Diet, Carbohydrate-Restricted | 4 | 2021 | 5 | 0.590 |
Why?
|
| Food Supply | 3 | 2019 | 67 | 0.580 |
Why?
|
| Treatment Outcome | 10 | 2019 | 3460 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2024 | 265 | 0.510 |
Why?
|
| Risk Assessment | 4 | 2024 | 1469 | 0.510 |
Why?
|
| Female | 38 | 2025 | 20363 | 0.480 |
Why?
|
| Body Weight | 1 | 2017 | 302 | 0.470 |
Why?
|
| Diet, Fat-Restricted | 3 | 2023 | 31 | 0.470 |
Why?
|
| Stress, Psychological | 1 | 2017 | 226 | 0.470 |
Why?
|
| Confidence Intervals | 2 | 2017 | 148 | 0.470 |
Why?
|
| Middle Aged | 25 | 2025 | 12202 | 0.450 |
Why?
|
| Research Design | 1 | 2017 | 334 | 0.440 |
Why?
|
| Male | 33 | 2025 | 19743 | 0.440 |
Why?
|
| Obesity | 8 | 2024 | 1179 | 0.430 |
Why?
|
| Adult | 26 | 2025 | 9586 | 0.420 |
Why?
|
| Blood Pressure | 4 | 2024 | 867 | 0.410 |
Why?
|
| Intensive Care Units, Neonatal | 3 | 2018 | 33 | 0.400 |
Why?
|
| HIV Infections | 4 | 2017 | 424 | 0.350 |
Why?
|
| Adolescent | 12 | 2024 | 3643 | 0.330 |
Why?
|
| Aged | 16 | 2025 | 10624 | 0.330 |
Why?
|
| Young Adult | 13 | 2024 | 2738 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2024 | 1477 | 0.300 |
Why?
|
| Retrospective Studies | 11 | 2025 | 3708 | 0.300 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 436 | 0.300 |
Why?
|
| Lipids | 2 | 2021 | 230 | 0.290 |
Why?
|
| Antihypertensive Agents | 2 | 2024 | 355 | 0.290 |
Why?
|
| Burnout, Professional | 2 | 2021 | 54 | 0.290 |
Why?
|
| Insulin Resistance | 3 | 2022 | 469 | 0.280 |
Why?
|
| Income | 2 | 2017 | 67 | 0.260 |
Why?
|
| Electronic Health Records | 3 | 2024 | 182 | 0.250 |
Why?
|
| Weight Loss | 5 | 2023 | 462 | 0.250 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 765 | 0.230 |
Why?
|
| Hypercalcemia | 1 | 2025 | 11 | 0.220 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2025 | 17 | 0.220 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 136 | 0.210 |
Why?
|
| Triglycerides | 3 | 2021 | 229 | 0.210 |
Why?
|
| Prediabetic State | 1 | 2024 | 74 | 0.210 |
Why?
|
| Child | 8 | 2024 | 2478 | 0.210 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 1580 | 0.200 |
Why?
|
| Risk Factors | 9 | 2024 | 4001 | 0.200 |
Why?
|
| Retinal Diseases | 1 | 2023 | 26 | 0.200 |
Why?
|
| Logistic Models | 3 | 2024 | 783 | 0.190 |
Why?
|
| United States | 6 | 2024 | 4132 | 0.190 |
Why?
|
| Diet Records | 2 | 2019 | 32 | 0.190 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 38 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2024 | 180 | 0.190 |
Why?
|
| Bacterial Infections | 1 | 2023 | 51 | 0.190 |
Why?
|
| Diabetic Retinopathy | 1 | 2023 | 73 | 0.190 |
Why?
|
| Insulin | 3 | 2022 | 369 | 0.190 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2022 | 4 | 0.190 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 7 | 0.190 |
Why?
|
| Environmental Pollutants | 1 | 2022 | 21 | 0.180 |
Why?
|
| Emergency Medicine | 1 | 2023 | 121 | 0.180 |
Why?
|
| Proteomics | 2 | 2020 | 102 | 0.180 |
Why?
|
| California | 5 | 2020 | 66 | 0.180 |
Why?
|
| Algorithms | 3 | 2019 | 517 | 0.180 |
Why?
|
| Viral Load | 3 | 2016 | 73 | 0.180 |
Why?
|
| Cholesterol, HDL | 2 | 2019 | 178 | 0.180 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 298 | 0.170 |
Why?
|
| Poverty | 2 | 2019 | 116 | 0.170 |
Why?
|
| Breast Feeding | 2 | 2018 | 47 | 0.170 |
Why?
|
| Cholesterol, Dietary | 1 | 2021 | 36 | 0.170 |
Why?
|
| Infant | 6 | 2023 | 1083 | 0.170 |
Why?
|
| Feeding Behavior | 2 | 2019 | 158 | 0.170 |
Why?
|
| Body Mass Index | 3 | 2020 | 908 | 0.170 |
Why?
|
| Tricuspid Valve | 1 | 2020 | 5 | 0.160 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2020 | 6 | 0.160 |
Why?
|
| Proteome | 1 | 2020 | 41 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 950 | 0.160 |
Why?
|
| Dental Care for Children | 1 | 2019 | 4 | 0.160 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 18 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2019 | 1852 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 32 | 0.160 |
Why?
|
| Mitral Valve | 1 | 2020 | 39 | 0.160 |
Why?
|
| Aortic Aneurysm | 1 | 2019 | 11 | 0.160 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2019 | 4 | 0.150 |
Why?
|
| Aneurysm, Dissecting | 1 | 2019 | 12 | 0.150 |
Why?
|
| Hair | 1 | 2019 | 28 | 0.150 |
Why?
|
| Pesticides | 1 | 2022 | 196 | 0.150 |
Why?
|
| Pulmonary Valve | 1 | 2019 | 11 | 0.150 |
Why?
|
| Hydrocortisone | 1 | 2019 | 57 | 0.150 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 178 | 0.150 |
Why?
|
| Patient Compliance | 3 | 2017 | 219 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 754 | 0.150 |
Why?
|
| Workplace | 1 | 2020 | 50 | 0.150 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 24 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2023 | 325 | 0.150 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2020 | 44 | 0.150 |
Why?
|
| Hemodynamics | 1 | 2020 | 162 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 112 | 0.150 |
Why?
|
| Pericardium | 1 | 2019 | 55 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2019 | 65 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2019 | 44 | 0.150 |
Why?
|
| Causality | 2 | 2019 | 39 | 0.150 |
Why?
|
| Pneumonia | 1 | 2019 | 64 | 0.150 |
Why?
|
| Suture Techniques | 1 | 2019 | 61 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2019 | 6 | 0.150 |
Why?
|
| Vegetables | 1 | 2019 | 40 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 11 | 0.150 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 23 | 0.150 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2019 | 10 | 0.150 |
Why?
|
| Fruit | 1 | 2019 | 56 | 0.150 |
Why?
|
| Lactation | 1 | 2018 | 16 | 0.150 |
Why?
|
| Genotype | 2 | 2018 | 731 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 81 | 0.140 |
Why?
|
| Health Status Indicators | 1 | 2019 | 74 | 0.140 |
Why?
|
| Dietary Fats | 1 | 2019 | 109 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2019 | 101 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 24 | 0.140 |
Why?
|
| Medicare | 1 | 2019 | 213 | 0.140 |
Why?
|
| Selenium | 1 | 2017 | 4 | 0.140 |
Why?
|
| Carotenoids | 1 | 2017 | 9 | 0.140 |
Why?
|
| Child, Preschool | 5 | 2020 | 1282 | 0.140 |
Why?
|
| Marital Status | 1 | 2017 | 23 | 0.130 |
Why?
|
| Computer Simulation | 2 | 2017 | 224 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 32 | 0.130 |
Why?
|
| Graft Survival | 1 | 2019 | 313 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 1308 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 310 | 0.130 |
Why?
|
| Social Class | 1 | 2017 | 93 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 55 | 0.130 |
Why?
|
| Vitamins | 1 | 2017 | 73 | 0.130 |
Why?
|
| Group Processes | 1 | 2017 | 15 | 0.130 |
Why?
|
| Organizational Culture | 1 | 2017 | 25 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2017 | 68 | 0.130 |
Why?
|
| Fasting | 1 | 2017 | 94 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2018 | 197 | 0.130 |
Why?
|
| Plasma | 1 | 2016 | 14 | 0.130 |
Why?
|
| Milk, Human | 1 | 2016 | 17 | 0.130 |
Why?
|
| Educational Status | 1 | 2017 | 183 | 0.130 |
Why?
|
| Antioxidants | 1 | 2017 | 116 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 204 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 25 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 22 | 0.130 |
Why?
|
| Cross Infection | 1 | 2017 | 56 | 0.130 |
Why?
|
| Software | 1 | 2017 | 128 | 0.130 |
Why?
|
| Health Status | 1 | 2019 | 403 | 0.130 |
Why?
|
| Radiation Pneumonitis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Prisons | 1 | 2016 | 5 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2017 | 123 | 0.120 |
Why?
|
| Overweight | 3 | 2024 | 263 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2017 | 187 | 0.120 |
Why?
|
| Radiology Information Systems | 1 | 2016 | 13 | 0.120 |
Why?
|
| Continental Population Groups | 1 | 2017 | 236 | 0.120 |
Why?
|
| Caloric Restriction | 1 | 2017 | 103 | 0.120 |
Why?
|
| Prisoners | 1 | 2016 | 12 | 0.120 |
Why?
|
| Smoking | 1 | 2020 | 531 | 0.120 |
Why?
|
| Carbamates | 1 | 2015 | 15 | 0.120 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2016 | 44 | 0.120 |
Why?
|
| Internet | 1 | 2017 | 201 | 0.120 |
Why?
|
| Workload | 1 | 2016 | 40 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2019 | 694 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 11 | 0.120 |
Why?
|
| Documentation | 1 | 2016 | 47 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 23 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2015 | 67 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 19 | 0.120 |
Why?
|
| Health Policy | 1 | 2016 | 93 | 0.110 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 61 | 0.110 |
Why?
|
| Diet | 1 | 2017 | 393 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 168 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 416 | 0.110 |
Why?
|
| Heart Failure | 2 | 2019 | 761 | 0.110 |
Why?
|
| Biometry | 1 | 2014 | 13 | 0.110 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 10 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 319 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 126 | 0.110 |
Why?
|
| Pregnancy | 4 | 2019 | 981 | 0.110 |
Why?
|
| Lung | 1 | 2016 | 268 | 0.110 |
Why?
|
| Inflammation | 1 | 2017 | 542 | 0.100 |
Why?
|
| Motivation | 1 | 2014 | 110 | 0.100 |
Why?
|
| Mass Screening | 1 | 2016 | 268 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 828 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 131 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2016 | 362 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 429 | 0.090 |
Why?
|
| Cytosine | 1 | 2011 | 10 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 13 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2011 | 51 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 770 | 0.090 |
Why?
|
| Adenoviridae | 1 | 2011 | 68 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 212 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 4057 | 0.080 |
Why?
|
| Propensity Score | 2 | 2019 | 48 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2021 | 173 | 0.080 |
Why?
|
| Hospitalization | 2 | 2023 | 495 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2022 | 880 | 0.070 |
Why?
|
| Observer Variation | 2 | 2020 | 96 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2024 | 2338 | 0.070 |
Why?
|
| Energy Intake | 2 | 2019 | 128 | 0.070 |
Why?
|
| Prevalence | 2 | 2023 | 1002 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 369 | 0.070 |
Why?
|
| SEER Program | 2 | 2018 | 33 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2017 | 196 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 894 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 471 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1246 | 0.050 |
Why?
|
| Contrast Media | 1 | 2025 | 139 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 194 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2023 | 8 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 2195 | 0.050 |
Why?
|
| Uric Acid | 1 | 2024 | 28 | 0.050 |
Why?
|
| Manikins | 1 | 2023 | 39 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2023 | 26 | 0.050 |
Why?
|
| Tracheostomy | 1 | 2023 | 28 | 0.050 |
Why?
|
| Disease Progression | 1 | 2024 | 594 | 0.050 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2022 | 1 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 329 | 0.040 |
Why?
|
| Life Style | 1 | 2024 | 409 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 188 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2022 | 500 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 131 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Child Behavior | 1 | 2019 | 24 | 0.040 |
Why?
|
| Tennessee | 1 | 2019 | 107 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 16 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2019 | 32 | 0.040 |
Why?
|
| Child Development | 1 | 2019 | 45 | 0.040 |
Why?
|
| Nutritional Requirements | 1 | 2019 | 16 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 1 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 25 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2019 | 23 | 0.040 |
Why?
|
| Reminder Systems | 1 | 2019 | 23 | 0.040 |
Why?
|
| Quinazolinones | 1 | 2019 | 7 | 0.040 |
Why?
|
| Aorta | 1 | 2019 | 127 | 0.040 |
Why?
|
| Reproductive History | 1 | 2018 | 5 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 54 | 0.040 |
Why?
|
| Parity | 1 | 2018 | 19 | 0.040 |
Why?
|
| Purines | 1 | 2019 | 21 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 71 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 89 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 72 | 0.040 |
Why?
|
| Sirolimus | 1 | 2019 | 33 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 445 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 71 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 282 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 75 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 128 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2019 | 48 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 77 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 467 | 0.040 |
Why?
|
| Gestational Age | 1 | 2018 | 129 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 10 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2019 | 205 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2019 | 66 | 0.030 |
Why?
|
| Tocopherols | 1 | 2017 | 3 | 0.030 |
Why?
|
| Mothers | 1 | 2018 | 91 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2019 | 201 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 413 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 43 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 281 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 2017 | 21 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 48 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 48 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 241 | 0.030 |
Why?
|
| Diet Therapy | 1 | 2017 | 15 | 0.030 |
Why?
|
| Allied Health Personnel | 1 | 2017 | 4 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 11 | 0.030 |
Why?
|
| Nurses | 1 | 2017 | 15 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 895 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 125 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 200 | 0.030 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2017 | 49 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 780 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1202 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 101 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 332 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 241 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 320 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 2016 | 1 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 543 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 99 | 0.030 |
Why?
|
| New Mexico | 1 | 2016 | 6 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 790 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 51 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 565 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 148 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 78 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 92 | 0.030 |
Why?
|
| Genomics | 1 | 2016 | 88 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2016 | 156 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 42 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 644 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 188 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1163 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 290 | 0.030 |
Why?
|
| Physicians | 1 | 2017 | 165 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 495 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2016 | 160 | 0.030 |
Why?
|
| Body Composition | 1 | 2016 | 391 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 193 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 576 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 166 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1547 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2287 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 486 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 412 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 2528 | 0.020 |
Why?
|
| African Americans | 1 | 2019 | 1425 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 837 | 0.020 |
Why?
|
| Stroke | 1 | 2017 | 610 | 0.020 |
Why?
|
| Exercise | 1 | 2016 | 687 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 151 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2011 | 108 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2011 | 134 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 882 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 7598 | 0.020 |
Why?
|